These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Choosing the analysis population in non-inferiority studies: per protocol or intent-to-treat. Matilde Sanchez M; Chen X Stat Med; 2006 Apr; 25(7):1169-81. PubMed ID: 16397861 [TBL] [Abstract][Full Text] [Related]
25. Missing data in the regulation of medical devices. Campbell G; Pennello G; Yue L J Biopharm Stat; 2011 Mar; 21(2):180-95. PubMed ID: 21390995 [TBL] [Abstract][Full Text] [Related]
26. Impact of missing data on type 1 error rates in non-inferiority trials. Yoo B Pharm Stat; 2010; 9(2):87-99. PubMed ID: 19408241 [TBL] [Abstract][Full Text] [Related]
27. [Missing data: warrant for search and capture]. Torres F; Pontes C Med Clin (Barc); 2013 Oct; 141(7):297-9. PubMed ID: 23706686 [No Abstract] [Full Text] [Related]
28. The analysis of incomplete data in the three-period two-treatment cross-over design for clinical trials. Richardson BA; Flack VF Stat Med; 1996 Jan; 15(2):127-43. PubMed ID: 8614750 [TBL] [Abstract][Full Text] [Related]
30. Etrank: a ranking procedure for handling missing data in clinical trials: application to venlafaxine extended-release depression clinical trial. Entsuah R J Biopharm Stat; 1996 Nov; 6(4):457-75. PubMed ID: 8969980 [TBL] [Abstract][Full Text] [Related]
31. The impact of missing data in a generalized integer-valued autoregression model for count data. Alosh M J Biopharm Stat; 2009 Nov; 19(6):1039-54. PubMed ID: 20183463 [TBL] [Abstract][Full Text] [Related]
32. Management and interpretation of data obtained from clinical trials in pain management. Theodore BR; Gatchel RJ Pain Pract; 2008; 8(6):461-72. PubMed ID: 19000174 [TBL] [Abstract][Full Text] [Related]
33. Missing data handling methods in medical device clinical trials. Yan X; Lee S; Li N J Biopharm Stat; 2009 Nov; 19(6):1085-98. PubMed ID: 20183466 [TBL] [Abstract][Full Text] [Related]
35. Missing data issues at the FDA Center for Biologics Evaluation and Research. Scott JA; Hsu H J Biopharm Stat; 2011 Mar; 21(2):196-201. PubMed ID: 21390996 [TBL] [Abstract][Full Text] [Related]
36. A guide to missing data for the pediatric nephrologist. Larkins NG; Craig JC; Teixeira-Pinto A Pediatr Nephrol; 2019 Feb; 34(2):223-231. PubMed ID: 29536258 [TBL] [Abstract][Full Text] [Related]
37. An alternative way to classify missing data mechanism in clinical trials--a dialogue on missing data. Wei L J Biopharm Stat; 2011 Mar; 21(2):355-61. PubMed ID: 21391007 [TBL] [Abstract][Full Text] [Related]
38. Who wants to be an ICH Euro billionaire? Gordon K Pharm Stat; 2008; 7(1):4-8. PubMed ID: 17370280 [TBL] [Abstract][Full Text] [Related]
39. Issues on the selection of non-inferiority margin in clinical trials. Hou Y; Wu XY; Li K Chin Med J (Engl); 2009 Feb; 122(4):466-70. PubMed ID: 19302756 [TBL] [Abstract][Full Text] [Related]
40. Assessment of relative improvement due to weights within generalized estimating equations framework for incomplete clinical trials data. Demirtas H J Biopharm Stat; 2004 Nov; 14(4):1085-98. PubMed ID: 15587981 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]